Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts on Near Term Uotrends -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (518)	1/21/2003 11:13:05 AM
From: Jibacoa	Read Replies (1) \| Respond to of 1404

CAMZ Up 254% today on volume of 3.147M after announcing that SunGard will pay $9 for CAMZ shares (the stock closed at $2.50 on Friday.<g>) The stock had been selling at 0.33 of book and 0.5 of sales and there had been some insider's buying.<g> I have a very small position on CAMZ and was waiting for it to close above its Dec.10-Dec.11 double top at the 3.55 level. Now with 20/20 hindside vision one can see that the stock's RSI has been steadily rising since Jan.6 and that there has been a persistent and significant positive money flow since Jan.10 (in spite of no significant increase in trading volume or price )I guess it may be one more lesson to learn and try to watch for for possible similar cases in the future.<g> siliconinvestor.com siliconinvestor.com Bernard

To: Jibacoa who wrote (518)	2/1/2003 8:23:50 AM
From: Sergio H	Read Replies (1) \| Respond to of 1404

Bernard, DFIB broke resistance at 2.50 and now looks good for a run over 3. This past week, DFIB received FDA approval for use of the Powerheart AED on youn children. The press release states that NY is currently the only state to require AEDs in every school with legislation pending in other states. <Cardiac Science President and CEO Raymond W. Cohen said, “The school market is expanding rapidly in both the U.S. and U.K. and we anticipate additional legislation, similar to New York State, which will continue to drive adoption of AEDs in schools. As a result this has become a very important segment for Cardiac Science, a segment in which we are clearly the market leader. We believe that FDA clearance of our new pediatric electrode system, specifically designed and validated for use on smaller patients, will help us to maintain our leadership position in that segment. We will immediately begin to ship these electrode systems, which sell for about $90, to all types of customers who are anxious to deploy the new electrode pads in areas where small children are at risk.”> finance.lycos.com